Publication date: Apr 29, 2019
In epsiode 6, Dr. Peter Beitsch, Chief Physician of the Dallas Surgical Group and an executive with the TME Breast Cancer Network, joined us to discuss his study published by the Clinical Journal of Oncology titled, Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? During the episode, he spoke in-depth about the results of that study and the implications for the future of precision medicine in cancer care. This episode is Part Two of that discussion in which we learn more about how Dr. Beitsch uncovered flaws in population-based cancer treatments and began to advocate for individualized patient care.
|Hereditary Breast Cancer|
|Treatment of cancer|
|Branches of biology|
- The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
- Precision Medicine in the Treatment of Breast Cancer of Relating Treatments to Mutation
- Individualized metabolomics: opportunities and challenges.